Effect of combination therapy with polyethylene glycol loxenatide and metformin on glucose and lipid metabolism in newly diagnosed obese patients with type 2 diabetes mellitus
Objective To explore the effect of combination therapy with polyethylene glycol loxenatide and metformin on glucose and lipid metabolism in newly diagnosed obese patients with type 2 diabetes mellitus.Methods A total of 80 newly diagnosed obese patients with type 2 diabetes mellitus were selected and divided into a control group and an observation group according to random number table method,with 40 cases in each group.The control group was given metformin monotherapy for hypoglycemia,and the observation group was given polyethylene glycol loxenatide based on the control group.The blood glucose level,blood lipid level,stress response indicators and drug safety were compared between the two groups before and after medication.Results After medication,the fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in the observation group were(5.87±0.85)mmol/L,(8.62±1.38)mmol/L and(6.12±0.94)%,which were lower than(7.02±1.14)mmol/L,(9.42±1.55)mmol/L and(7.23±1.21)%in the control group,and the difference was statistically significant(P<0.05).The high density lipoprotein cholesterol in the observation group was(1.13±0.17)mmol/L,which was higher than(1.05±0.15)mmol/L in the control group;the total cholesterol,triglyceride and low density lipoprotein cholesterol in the observation group were(4.05±0.71),(1.87±0.56)and(2.21±0.65)mmol/L,which were lower than(4.69±0.83),(2.23±0.68)and(2.69±0.71)mmol/L in the control group;the difference was statistically significant(P<0.05).After medication,the serum levels of hypersensitive C-reactive protein,interleukin-6 and malondialdehyde in the observation group were(6.24±0.65)mg/L,(5.79±0.71)ng/L and(4.70±0.89)μmol/L,which were lower when compared with(7.88±0.87)mg/L,(6.32±1.01)ng/L and(5.41±1.05)μmol/L in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the percentage of adverse drug reactions between the two groups(P>0.05).Conclusion Polyethylene glycol loxenatide combined with metformin in the treatment of newly diagnosed obese patients with type 2 diabetes mellitus can better regulate the glucose and lipid metabolism of patients,reduce the body's stress response,and ensure the safety of medication.
Obese type 2 diabetes mellitusPolyethylene glycol loxenatideMetforminGlucose and lipid metabolismSafety
NETL
NSTL
万方数据
